Roche's CMO Horning to retire, Lilly's high-flyer Garraway s...

Roche’s influential chief medical officer Sandra Horning is to retire at the end of the year, the company has confirmed, to be replaced by a high-flyer from rival Eli Lilly.

Lilly faces biosimilar rivals to osteoporosis drug Forsteo i...

2nd RNA Targeted Drug Discovery Summit

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 

Lilly firms up case for Emgality in migraine market chase

Lilly dips as biomed chief Christi Shaw heads to Gilead

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...